MedTrace Logo

Pharmacokinetics and Safety Study of LBAL in Healthy Subjects

NCT02206867 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2015-06-15

No results posted yet for this study

Summary

To compare PK, safety and tolerability of LBAL developed by LG Life Sciences Ltd. With those of Humira®.

Conditions

  • Healthy Subjects

Interventions

BIOLOGICAL

LBAL

Anti-inflammatory agents

BIOLOGICAL

Humira

Anti-inflammatory agents

Sponsors & Collaborators

  • LG Life Sciences

    lead INDUSTRY

Principal Investigators

  • Kyung-Sang Yu, M.D., Ph.D., M.B.A · Dep. of Clnical Pharmacology, Seoul National University College of Medicine and Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2015-02-28
Completion
2015-02-28

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02206867 on ClinicalTrials.gov